/
Company Overview We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management.
$1.53
$0.03 (-1.61%)
EOD Jul 17, 2026
10.55% operating margin is respectable but not wide. ROIC at 19.09%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 17.5% YoY. Margins deteriorated 6.7pp alongside, both lines moving the wrong way.
ROIC dropped from 94.21% to 19.09%, capital efficiency is deteriorating. Operating margin contracted 6.7pp YoY, cost discipline may be slipping.
1.8x earnings, 7.7x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$36M
▼ -17.5% YoY
Net Income (TTM)
$24M
▲ +266.7% YoY
Op. Margin
9.32%
▼ -6.7pp YoY
ROIC
19.05%
▼ -75.1pp YoY
Cash Flow & Balance Sheet
FCF (FY)
$5M
▲ +45.2% YoY
Op. Cash Flow (TTM)
$5M
▲ +25.5% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$3M
3Y CAGR: +89.6%
Continue Research
At a P/E of 1.8 and a price-to-free-cash-flow of 7.7, Interpace Biosciences (IDXG) trades below a two-stage DCF intrinsic value of about $10.03 per share, so at $1.53 the stock looks undervalued (557.8% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Interpace Biosciences scores 88/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $10.03 per share for IDXG, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $7.52. At today's $1.53, that puts the stock about 557.8% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Interpace Biosciences scores 88 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 9.3% operating margin and a 19.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. IDXG currently trades below its estimated intrinsic value and scores 88/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.